Journal Article10.1182/BLOOD.V128.22.3654.3654
Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study
Julie Kanter,Lori E. Heath,Chunmei Zhou,Tsiri Agbenyega,Raffaella Colombatti,Carlton Dampier,Hoda Hassab,Deepa Manwani,Nancy Robitaille,Patricia B. Brown,Joseph A. Jakubowski,Suqin Yao,Jack Knorr,Carolyn Hoppe +13 more
2
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Alexis A. Thompson,Mark C. Walters,Janet L. Kwiatkowski,John E.J. Rasko,John E.J. Rasko,John E.J. Rasko,Jean-Antoine Ribeil,Suradej Hongeng,Elisa Magrin,Gary J. Schiller,Emmanuel Payen,Michaela Semeraro,Despina Moshous,François Lefrère,Hervé Puy,Philippe Bourget,Alessandra Magnani,Laure Caccavelli,Jean-Sebastien Diana,Felipe Suarez,Fabrice Monpoux,Valentine Brousse,Catherine Poirot,Catherine Poirot,Chantal Brouzes,Jean-François Meritet,Corinne Pondarré,Yves Beuzard,Stany Chrétien,Thibaud Lefebvre,David T. Teachey,Usanarat Anurathapan,P. Joy Ho,P. Joy Ho,Christof von Kalle,Morris Kletzel,Elliott Vichinsky,Sandeep Soni,Gabor Istvan Veres,Olivier Negre,Robert W. Ross,David Davidson,Alexandria Petrusich,Laura Sandler,Mohammed Asmal,Olivier Hermine,Mariane de Montalembert,Salima Hacein-Bey-Abina,Stéphane Blanche,Philippe Leboulch,Philippe Leboulch,Philippe Leboulch,Marina Cavazzana +52 more
TL;DR: Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long‐term red‐cell transfusions in 22 patients with severe β‐thalassemia without serious adverse events related to the drug product.
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
Saeed Dastgiri,Roya Dolatkhah +1 more
TL;DR: There is currently no reliable evidence to support or refute the perceived benefits of blood transfusions as treatment options; very limited information about any of the potential harms associated with these interventions or indeed guidance that can be used to aid clinical decision making.
59